as of 11-19-2026 3:59pm EST
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 223.8M | IPO Year: | 2016 |
| Target Price: | N/A | AVG Volume (30 days): | 499.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 0.09 | EPS Growth: | -60.98 |
| 52 Week Low/High: | $2.65 - $7.11 | Next Earning Date: | 11-09-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -43.38% | Revenue Growth (next year): | 194.92% |
| P/E Ratio: | 30.89 | Index: | |
| Free Cash Flow: | 43.4M | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 9, 2026 · 49% conf.
1D
+5.56%
$3.46
Act: -2.61%
5D
+12.91%
$3.70
20D
+9.21%
$3.58
2 ef20085184_ex99-1.htm
Exhibit 99.1
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
•
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October
•
Corporate Update Conference Call Today at 4:30 PM ET
NEW YORK, November 9, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2026.
“While we continue to work with the U.S. Government toward a new TPOXX procurement contract, our international business remains an important part of our strategy,” stated Diem Nguyen, Chief Executive Officer. “We recently announced a $15 million contract with the Canadian Department of National Defence, a longstanding customer, and are actively pursuing opportunities with other international governments to further diversify our customer base over time.”
Summary Financial Results
($ in millions, except
per share amounts)
Three Months
Ended September 30
Nine Months
Ended September 30
2026
2025
2026
2025
Product sales (1)
$
0.2
$
0.9
$
41.6
$
85.8
Total revenues (2)
$
1.3
$
2.6
$
48.6
$
90.8
Operating (loss)/income(3) (4)
$
(6.5
)
$
(10.2
)
$
2.1
$
33.2
(Loss)/income before income taxes(3)
$
(5.5
)
$
(8.4
)
$
5.3
$
38.3
Net (loss)/income
$
(2.9
)
$
(6.4
)
$
6.1
$
28.7
Diluted (loss) / income per share
$
(0.04
)
$
(0.09
)
$
0.09
$
0.40
(1)
Includes supportive services related to product sales.
(2)
Includes research and development revenues.
(3)
Operating (loss)/income excludes, and (loss)/income before income taxes includes, other income. Both line items exclude the impact of income taxes.
(4)
Differences in operating (loss)/income margin between periods reflect different product mixes in those periods.
Year-to-Date Business and Operational Activity
•
In October, the Canadian Department of National Defence (CDND) awarded a contract to SIGA for the procurement of oral TPOXX. The contract provides for the purchase of up to approximately $15 million of oral TPOXX by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately $6 million is subject to option exercise by the CDND.
•
For the nine months ended September 30, 2026, the Company delivered approximately $13 million of oral TPOXX to two international customers.
•
For the nine months ended September 30, 2026, the Company delivered approximately $26 million of IV TPOXX to the U.S. Strategic National Stockpile (SNS) under the 19C contract, fulfilling the final procurement order under that contract.
Year-to-Date Capital Management Activity
On March 26, 2026, a special cash dividend of $0.60 per share was declared, and was paid on April 23, 2026, to shareholders of record at the close of business on April 7, 2026.
Retirement of Chief Scientific Officer
Dennis Hrubry, Ph.D., Executive Vice President and Chief Scientific Officer, will retire effective today, concluding more than 30 years with the Company. Following his retirement, Dr. Hruby will continue to support the Company in an advisory capacity.
Conference Call and Webcast
SIGA will host a conference call and webcast to provide a business update today, Monday, November 9, 2026, at 4:30 P.M. ET.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A live webcast of the call will also be available on the Company's website at www.siga.com in the Investor Relations section of the website. Please log in approximately 5-10 minutes prior to the scheduled start time.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130564. The archived webcast will be available in the Investor Relations section of the Company's website.
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business performance and plans. Forward-looking statements include statements
Aug 6, 2026 · 100% conf.
1D
-7.44%
$2.89
Act: -2.24%
5D
-13.90%
$2.69
Act: -7.69%
20D
-16.40%
$2.61
Transcript text not available. View on SEC.gov →
May 7, 2026 · 100% conf.
1D
-8.72%
$4.32
Act: +1.59%
5D
-14.47%
$4.05
Act: -9.94%
20D
-17.45%
$3.90
Act: -9.09%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784333823.a7476239
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how SIGA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SIGA SIGA Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.